The Denosumab phase-3 trial due to report any day has progression-free survival as the primary endpoint.
It's Bone Metastasis-Free Survival. But patients enrolled in the trials couldn't have prior or current evidence of radiographically detectable bone metastasis, which is entirely different from EXEL184.
I don't know how else to convince you Denosumab and XL184 are NOT competing drugs.
Market Data 
Markets 
AI
